St. Gallen/Vienna 2015: A Brief Summary of the Consensus Discussion

Gnant, Michael; Thomssen, Christoph; Harbeck, Nadia

doi:10.1159/000430488

Cited by 86 publications

(74 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Following scoring, the tumours were classified based on the expression of ER, PR, HER2, basal markers (CK5, CK14) and Ki67 into 5 taxonomic subtypes as previously described [16,17]. …”

Section: Methodsmentioning

confidence: 99%

Histological Features and Tissue Microarray Taxonomy of Nigerian Breast Cancer Reveal Predominance of the High-Grade Triple-Negative Phenotype

Titloye

Foster

et al. 2016

Pathobiology

View full text Add to dashboard Cite

Introduction: Little is known about the biology, molecular profile and hence optimal treatment of African Nigerian breast cancer. The aim of this work, therefore, was to characterize the histology and molecular profile of Nigerian breast cancer. Methods: Breast carcinomas from women at 6 centres of similar tribal origin in Nigeria were reviewed and assembled into tissue microarrays (TMAs), and sections were stained for hormone receptors, i.e. estrogen receptor (ER)α, ERβ1, ERβ progesterone receptor (PR) and androgen receptor, cyclin D, HER2, Ki67 and cytokeratins (CKs), i.e. CK5/6 and CK14 (basal) and CK18 and 19 (luminal). Results: A total of 835 tumours were analysed. The mean age at diagnosis was 48.62 ± 12.41 years. The most common histological subtype was ductal NST (no-special-type) carcinoma (87.3%). Over 90% of the tumours were grade 2 or 3. The predominant molecular phenotype was the non-basal, triple-negative type (47.65%) followed by the HER2-positive group (19.6%). The percentage of ER-, PR- and HER2-positive tumours was 22.4, 18.9 and 18.8%, respectively. Conclusion: Nigerian breast cancer predominantly has a high-grade, triple-negative profile. It occurs at a younger age and bears similarities at the molecular level to pre-menopausal breast cancer in white women, with remarkably lower levels of ERβ expression. The early presentation and histological and molecular phenotype may explain the poor prognosis, and tailoring treatment strategies to target this unique profile are required.

show abstract

“…Following scoring, the tumours were classified based on the expression of ER, PR, HER2, basal markers (CK5, CK14) and Ki67 into 5 taxonomic subtypes as previously described [16,17]. …”

Section: Methodsmentioning

confidence: 99%

Histological Features and Tissue Microarray Taxonomy of Nigerian Breast Cancer Reveal Predominance of the High-Grade Triple-Negative Phenotype

Titloye

Foster

et al. 2016

Pathobiology

View full text Add to dashboard Cite

show abstract

“…The definition of negative ER status by immunohistochemistry (IHC) is not concordant in the literature, with some definitions considering ER expression to be significant only if at least 10% of tumor cells express the receptors. However, the St. Gallen guidelines [1], the American Society of Clinical Oncology [2], and the American College of Pathology [3] have defined TNBC as breast cancer with less than 1% of tumor cells expressing ER and PR via IHC. It is widely accepted that TNBC is a very inhomogeneous group.…”

Section: Introductionmentioning

confidence: 99%

Biological Subtypes of Triple-Negative Breast Cancer

2017

View full text Add to dashboard Cite

Triple-negative breast cancers (TNBCs) are defined as tumors that are negative for estrogen, progesterone and HER-2 receptor. At a percentage of 10-20% TNBCs represent a minority in all breast cancers. However, because of the poor prognosis this particular subtype, triple negative disease accounts for a disproportionate number of metastatic cases and breast cancer deaths. Identification of its subtypes is essential for understanding the biological characteristics and clinical behavior of TNBC, as well as for developing personalized treatments. This review will focus on the great progress that has been made in the past few years on identifying new targets in TNBC subtypes and a variety of new treatment options that are on the verge of routine clinical application.

show abstract

“…Gallen Consensus Conference on early breast cancer is conducted which provided mostly evidence-based, globally valid treatment recommendations for breast cancer care, with a broad spectrum of acceptable clinical practice [13]. In the year 2015, Vienna, Austria conducted St. Gallen Consensus Conference on early breast cancer, and some recommendations on the current and newer practices were added to the official St. Gallen Consensus publication [14]. These are the globally accepted recommendations for the management of breast cancer.…”

Section: Background and Methodsmentioning

confidence: 99%